Health Care and the 2008 Election: Revolution, Reform, or Return to Business as Usual?
Executive Summary
As the presidential race heats up, health care executives say they have many reasons to be excited--and nervous. BCG reviews an industry-wide survey on the implications of the candidates' health care proposals for the pharma and device industries.
You may also be interested in...
Bending The Cost Curve: Harvard's Cutler Says Rx Can Play A Big Role
Health care cost trends may not be so bad after all, former Obama advisor writes in New England Journal of Medicine. Prescription drugs can help, he writes-but not entirely in the way industry would hope.
FDA and Health Care Reform: An Activist Agenda for the Agency
Everyone is gearing up for a debate over health care reform in 2009-including the Food & Drug Administration. The regulator's role may be bigger than you think.
FDA Puts Dose Selection At Top Of Agenda For End-Of-Phase 2A Meetings
Drug sponsors should use end-of-Phase 2A meetings for the in-depth discussions with FDA regarding dose estimation and selection that other pre-submission meetings do not allow for, according to a 1draft guidance